Dr. Tripathy Discusses Impact of T-DM1 in HER2+ Breast Cancer

Debu Tripathy, MD
Published: Monday, Jan 07, 2019



Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the impact of ado-trastuzumab emtansine (T-DM1; Kadcyla) in HER2-positive breast cancer.

The results from the KATHERINE trial presented at the 2018 San Antonio Breast Cancer Symposium are notable because they essentially impact practice immediately, says Tripathy. Treatment with T-DM1 nearly halved the number of recurrences in patients who had residual disease from standard neoadjuvant therapy. Although some patients had to come off therapy early due to adverse events, T-DM1 seemed to be well-tolerated overall, Tripathy adds.

Results from the phase III trial showed that the 3-year invasive disease-free survival (iDFS) rate was 88.3% with T-DM1 versus 77.0% with trastuzumab. The iDFS benefit with T-DM1 was upheld across key patient subgroups, according to data published in the New England Journal of Medicine.
SELECTED
LANGUAGE


Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the impact of ado-trastuzumab emtansine (T-DM1; Kadcyla) in HER2-positive breast cancer.

The results from the KATHERINE trial presented at the 2018 San Antonio Breast Cancer Symposium are notable because they essentially impact practice immediately, says Tripathy. Treatment with T-DM1 nearly halved the number of recurrences in patients who had residual disease from standard neoadjuvant therapy. Although some patients had to come off therapy early due to adverse events, T-DM1 seemed to be well-tolerated overall, Tripathy adds.

Results from the phase III trial showed that the 3-year invasive disease-free survival (iDFS) rate was 88.3% with T-DM1 versus 77.0% with trastuzumab. The iDFS benefit with T-DM1 was upheld across key patient subgroups, according to data published in the New England Journal of Medicine.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x